Circle Pharma, Inc.

SOUTH SAN FRANCISCO, CA · Founded 2012 · Biotech · Private

Macrocyclic small-molecule therapeutics for cancer and serious diseases

Claim this profile

Follows are private to you and power your alerts

Updated · circlepharma.com

Sector
Biotech
Headquarters
SOUTH SAN FRANCISCO, CA
Founded
2012
Latest Form D
$54.2M, Jul 2024
Total capital
$109M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$109M
4 Form D · last Jul 2024
28 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
1
14 pending · first 2022
Rank in peer group#481 of 1449

Capital timeline

20162018202020222024FEDERAL ↑EQUITY ↓Cumulative $109M1st Form D$3.8M2nd Form D$15M3rd Form D$35.7M4th Form D$54.2M
20162018202020222024FEDERAL ↑EQUITY ↓Cumulative $109M2nd Form D$15M4th Form D$54.2M

Latest events

  • Private capital raisedForm D · SEC · 4th filing$54.2M
  • Private capital raisedForm D · SEC · 3rd filing$35.7M
  • Private capital raisedForm D · SEC · 2nd filing$15M
  • Private capital raisedForm D · SEC · 1st filing$3.8M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#481 · top 33%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Cayla J. McEwenExecutive OfficerNamed in SEC Form D filings
  • David EarpExecutive Officer, DirectorNamed in SEC Form D filings
  • Douglas R. CrawfordDirectorNamed in SEC Form D filings
  • Elton J. SatuskyExecutive OfficerNamed in SEC Form D filings
  • James H. EvangelistaDirectorNamed in SEC Form D filings
  • John JoseyDirectorNamed in SEC Form D filings
Show all 13 people
  • Matthew P. JacobsonDirectorNamed in SEC Form D filings
  • Paul H. ParkExecutive OfficerNamed in SEC Form D filings
  • Peter SvennilsonDirectorNamed in SEC Form D filings
  • Scott R. LokeyDirectorNamed in SEC Form D filings
  • Stephen H. KelseyDirectorNamed in SEC Form D filings
  • Thilo H. SchroederDirectorNamed in SEC Form D filings
  • Walter P. MoosDirectorNamed in SEC Form D filings

What it has protected

USPTO · 1 granted of 15
  • PendingCyclin InhibitorsUSPTOApplication 18667080
  • PendingCyclin InhibitorsUSPTOApplication 18491380
  • GrantedCyclative Release Of Peptidic CompoundsUSPTOUS 11,299,513
Show all 15 patent records
  • Cyclin InhibitorsDec 12, 2024 · Application 18667080Pending
  • Cyclin InhibitorsJul 4, 2024 · Application 18491380Pending
  • Cyclative Release Of Peptidic CompoundsApr 12, 2022 · US 11,299,513Granted
  • Cyclin InhibitorsApplication 63637984Pending
  • Cyclin InhibitorsApplication 63637995Pending
  • Cyclin InhibitorsApplication 63638000Pending
  • Cyclin InhibitorsApplication 63612533Pending
  • Cyclin InhibitorsApplication PCTUS2023077448Pending
  • Cyclin InhibitorsApplication 63467651Pending
  • Cyclin InhibitorsApplication 63380562Pending
  • Cyclative Release Of Peptidic CompoundsApplication PCTUS2018044182Pending
  • Cyclin InhibitorsApplication PCTUS2025026047Pending
  • Cyclative Release Of Peptidic CompoundsApplication 62538477Pending
  • Cyclin InhibitorsApplication PCTUS2025026045Pending
  • Cyclin InhibitorsApplication PCTUS2024029839Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .